No significant correlations between the pre-treatment CRP level and the remaining baseline patient characteristics including patient age (p = 0.055), sex (p = 0.790), co-morbidities (p = 0.849), smoking status (p = 0.112), tumor site (p = 0.379), clinical stage (p = 0.350), nodal involvement (p = 0.343), tumor grade (p = 0.940), extramural venous involvement (EMVI, p = 0.844), lactate dehydrogenase (LDH, p = 0.620), carcinoembryonic antigen (CEA, p = 0.196), and carbohydrate antigen (CA 19-9, p = 0.175) were detected. This evidence concerns the gene CEACAM5 and neoplasm.